Earnings
Even as Novartis entertains the potential sale of Sandoz, the company is lauding growth in its biosimilars business that is expected to stabilize its future development.
In a new “Measuring the Return from Pharmaceutical Innovation” report by Deloitte’s Center for Health Solutions, returns from R&D innovation are up by 7% across the industry.
The union has one primary goal – speed up discovery and development to get effective drugs to patients sooner.
A new report showed the increased funding in 2021 mirrors national data that show accelerated financing in support of new therapies for multiple diseases, driven by COVID-19 concerns.
The amount will be used to enhance research and development efforts for KYV-101 that has a strong potential to treat different types of autoimmune illnesses.
Leyden Labs secured $140 million in a Series B financing round. Combined with $40 million from a Series A round in March 2021, the company has significant funding to advance its portfolio of candidates.
Cellino is a closed loop cell therapy manufacturing company that aims to make stem cell-based regenerative therapies available to all eligible patients and researchers using cells in clinical research.
UCB has announced that it is acquiring Zogenix as part of plans to expand its reach into commercializing and developing treatments for rare diseases.
The approval of Cibinqo was based on data from five clinical trials of more than 1,600 people. Safety and efficacy were studied in three Phase III trials.
GlaxoSmithKline has declined all three of Unilever PLC’s offers to acquire its Consumer Healthcare business, saying that the proposal undervalued the division’s present and further worth.
PRESS RELEASES